2020 Lautenberg Center Progress Report

More documents

Recommendations

Info

8 MSc and PhD students that graduated: PhD Julia kanterman Yaron Meirow MSc Kerem Ben-Meir Nira Twaik-Nakav Hadas Ashkenazi Or Reuven
NEW THERAPEUTICS TO COMBAT ACUTE MYELOID LEUKEMIA Yinon Ben-Neriah Lay language summary Acute myeloid leukemia is one of the most aggressive types of cancer and despite the progress made in its treatment lately, the 5-year survival rate for people 20 and older with AML is only about 25% and seldom there is a cure to the disease. Following an intensive research and development effort our research team succeeded in developing a biological drug, which was found to cure up to 50% of model mice of poor risk human leukemia and eradicate human leukemia transplanted to model mice. Leukemia cells produce many proteins which are barely made in normal blood cells, working in concert to provide the leukemic cell growth advantage and death protection even upon chemotherapy. Biological cancer drugs developed so far, mostly attack a single leukemic protein and the leukemic cells quickly find a way to avoid the drug effect through alternative proteins. Unlike most modern cancer drugs, our newly developed drug works like a cluster bomb that attacks simultaneously many leukemic proteins and thus makes it difficult for the leukemia cell to evade the therapy. Another important advantage of the new drug is its capacity to eradicate leukemia stem cells, which is a big challenge in cancer therapy and one of the main reasons for failing to cure cancer. Based on our preclinical studies at the Lautenberg Center our experimental drug, which is the first of its kind, received an FDA approval for clinical trial, and a phase 1 trial was initiated this year at the Memorial Sloan Kettering Cancer Center and soon at two other major centers in the US. 9
Page 1 and 2: 1
Page 3 and 4: MOLECULAR BASIS OF CARCINOGENESIS A
Page 5 and 6: 5 19. Oster S, Aqeilan R.I. Mapping
Page 7: 7 Publications (2016 - 2020): 1. Is
Page 11 and 12: 11 PhD students recently graduated:
Page 13 and 14: 13 3. IL-17+ CD8+ T cell suppressio
Page 15 and 16: A NOVEL ANTI-INFLAMMATORY PEPTIDE W
Page 17 and 18: PROFILING PANCREATIC PREINVASIVE LE
Page 19 and 20: HEPATIC INFLAMMATION AND METABOLISM
Page 21 and 22: 21 11. Hanin G, Yayon N, Tzur Y, Ha
Page 23 and 24: PREDICTION AND PREVENTION OF CONGEN
Page 25 and 26: 25 12. Glasner A, Oiknine-Djian E,
Page 27 and 28: 27 31. Alfi O, From I, Yakirevitch
Page 29 and 30: NATURAL KILLER CELL FUNCTION IN PRE
Page 31 and 32: 31 13. Obiedat A, Charpak-Amikam Y,
Page 33 and 34: 33 33. Glasner A, Levi A, Enk J, Is
Page 35 and 36: 35 Awards: The Rappaport Award for
Page 37 and 38: 37 Publications (2016 - 2020): 1. W
Page 39 and 40: 39 21. Emma Hajaj, Galit Eisenberg,
Page 41 and 42: integrate these data and predict on
Page 43: 43 Funding and Awards: 1. Concern F

2020 Lautenberg Center Progress Report

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?